Keyphrases
Response to Treatment
100%
Caucasian Patients
100%
Bevacizumab
100%
Choroidal
100%
Intravitreal Ranibizumab
100%
Polypoidal
100%
Central Macular Thickness
75%
Polypoidal Choroidal Vasculopathy
75%
Subretinal Fluid
50%
Visual Acuity
25%
Nave
25%
Monotherapy
25%
Clinical Parameters
25%
Mean Gain
25%
Treatment Response
25%
Visual Outcome
25%
Anatomical Outcome
25%
Aflibercept
25%
Intravitreal Bevacizumab
25%
Submacular Hemorrhage
25%
Choroidal Thickness
25%
Pachyvessel
25%
Nursing and Health Professions
Bevacizumab
100%
Central Macular Thickness
42%
Polypoidal Choroidal Vasculopathy
42%
Monotherapy
14%
Bleeding
14%
Optical Coherence Tomography
14%
Visual Acuity
14%
Treatment Response
14%
Aflibercept
14%
Subretinal Fluid
14%
Choroidal Thickness
14%
Medicine and Dentistry
Bevacizumab
100%
Polypoidal Choroidal Vasculopathy
42%
Bleeding
14%
Monotherapy
14%
Retrospective Study
14%
Visual Acuity
14%
Optical Coherence Tomography
14%
Treatment Response
14%
Subretinal Fluid
14%
Aflibercept
14%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Polypoidal Choroidal Vasculopathy
42%
Monotherapy
14%
Bleeding
14%
Retrospective Study
14%
Aflibercept
14%
Subretinal Fluid
14%
Neuroscience
Bevacizumab
100%
Vascular Disease
42%
Aflibercept
14%